Magee Daniel, Tharakan Ninan, Yuiminaga Yuigi
Department of Urology, Royal Perth Hospital, Perth, WA, Australia.
Res Rep Urol. 2025 Mar 18;17:87-94. doi: 10.2147/RRU.S516994. eCollection 2025.
Bladder cancer is the 10 most common cancer worldwide. The investigation and surveillance commonly involve a combination of upper tract imaging along with visual assessment of the bladder via cystoscopy. This study determined the validity of using Cxbladder Triage (CxbT) and Cxbladder Monitor (CxbM) as a suitable adjunct in ruling out urothelial carcinoma (UC) when investigating haematuria or monitoring for recurrence.
A single centre prospective study where the patients have been referred for investigation of UC or those on routine surveillance of known UC. All patients were counselled with consent obtained prior to midstream urine collection pre-cystoscopy in line with local protocol for urine-analysis to screen for infection with the residual specimen collected for the CxbT or CxbM test. De-identified patient demographic data along with smoking status, risk of environmental exposures, family history, type of hematuria or last date of last recurrence were collected, and the planned cystoscopy would then proceed. The data pertaining to exposure to smoking and type of haematuria are the symptoms and risk factors that are taken into account with CxbT or CxbM to calculate a score, which can then be correlated with the outcome at the end with cystoscopic and imaging investigations.
A combined 236 patients were recruited (CxbT = 134, CxbM = 102) with results showing excellent negative predictive value of 96.43% and 95.16%, respectively. A key result showed that CxbT in combination with upper tract imaging done as routine was able to rule out UC completely in low-risk patients.
We have validated the use of Cxbladder as an adjunct in the investigation and surveillance of UC. It is a non-invasive, accurate and reproducible test that can aid in ruling out UC, specifically for low-risk patients.
膀胱癌是全球第10大常见癌症。其检查和监测通常包括上尿路成像以及通过膀胱镜对膀胱进行视觉评估。本研究确定了在血尿检查或复发监测中，使用Cxbladder Triage（CxbT）和Cxbladder Monitor（CxbM）作为排除尿路上皮癌（UC）的合适辅助手段的有效性。
一项单中心前瞻性研究，研究对象为因UC检查而转诊的患者或已知UC的常规监测患者。所有患者均按照当地尿液分析方案接受咨询，并在膀胱镜检查前进行中段尿采集前获得同意，以筛查感染，剩余标本用于CxbT或CxbM检测。收集去识别化的患者人口统计学数据以及吸烟状况、环境暴露风险、家族史、血尿类型或最后一次复发日期，然后进行计划的膀胱镜检查。与吸烟暴露和血尿类型相关的数据是CxbT或CxbM用于计算分数时考虑的症状和风险因素，然后可以将其与膀胱镜检查和影像学检查最终结果相关联。
共招募了236名患者（CxbT = 134，CxbM = 102），结果显示阴性预测值分别高达96.43%和95.16%。一项关键结果表明，CxbT与常规进行的上尿路成像相结合能够在低风险患者中完全排除UC。
我们已经验证了Cxbladder作为UC检查和监测辅助手段的用途。它是一种无创、准确且可重复的检测方法，有助于排除UC，特别是对于低风险患者。
